Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEOMETRY-E: capmatinib + osimertinib versus platinum-pemetrexed chemotherapy in EGFR-mutant, MET-amplified, T790M-negative advanced NSCLC
jRCT2041210072Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of capmatinib and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Dec 2021; status: completed.
02
Drugs
capmatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210072.